Literature DB >> 18090328

Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease.

Masahiko Suzuki1, Mitsuyoshi Urashima, Hisayoshi Oka, Masaya Hashimoto, Kenichiro Taira.   

Abstract

Cardiac iodine-123-labeled-metaiodobenzylguanidine uptake is reduced in early-stage Parkinson's disease, suggesting sympathetic nerve degeneration. The scintigraphic findings in patients with Parkinson's disease with different clinical features have, however, not been established. Iodine-123-labeled-metaiodobenzylguanidine myocardial scintigraphy was performed in 143 patients with Parkinson's disease. The early and delayed heart to mediastinum ratios were analyzed according to the dominant motor deficit (tremor, bradykinesia, rigidity, and postural instability), age, sex, age at onset, disease duration, and Hoehn and Yahr stage. Both ratios correlated with bradykinesia, age at disease onset, and disease duration; but not with sex, Hoehn and Yahr stage, tremor, rigidity, and postural instability. Our results suggest a close link between myocardial sympathetic degeneration and bradykinesia, age at onset and disease duration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090328     DOI: 10.1097/WNR.0b013e3282f1ab33

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  8 in total

1.  Nocturnal hypertension and dysautonomia in patients with Parkinson's disease: are they related?

Authors:  Koldo Berganzo; Begoña Díez-Arrola; Beatriz Tijero; Johanne Somme; Elena Lezcano; Verónica Llorens; Iratxe Ugarriza; Roberto Ciordia; J C Gómez-Esteban; Juan J Zarranz
Journal:  J Neurol       Date:  2013-02-15       Impact factor: 4.849

2.  Is heart rate variability related to gait impairment in patients with Parkinson's disease? A pilot study.

Authors:  M B Aerts; N E Synhaeve; A Mirelman; B R Bloem; N Giladi; J M Hausdorff
Journal:  Parkinsonism Relat Disord       Date:  2009-03-28       Impact factor: 4.891

3.  Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease.

Authors:  Jörg Spiegel
Journal:  Parkinsons Dis       Date:  2009-12-22

Review 4.  Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Authors:  Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-07-14       Impact factor: 3.575

5.  Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys.

Authors:  Valerie Joers; Kailie Seneczko; Nichole C Goecks; Timothy J Kamp; Timothy A Hacker; Kevin G Brunner; Jonathan W Engle; Todd E Barnhart; R Jerome Nickles; James E Holden; Marina E Emborg
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

Review 6.  (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.

Authors:  Eun Joo Chung; Sang Jin Kim
Journal:  J Mov Disord       Date:  2015-05-31

7.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

8.  Ultrasonography of the Vagus Nerve in Parkinson's Disease.

Authors:  Nadin Fedtke; Otto W Witte; Tino Prell
Journal:  Front Neurol       Date:  2018-07-02       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.